Diverging Performance of KOSDAQ Active ETFs and Timefolio’s Growing Pains
KOSDAQ active ETFs have shown notably diverging performances since their listing. The 'TIME KOSDAQ Active' ETF dropped 14.72%, underperforming the broader KOSDAQ market, while 'KoAct KOSDAQ Active' recorded a smaller decline of 7.03%, closely matching the index’s loss. The difference in performance can be attributed to a portfolio focus on highly volatile small- and mid-cap growth stocks. Furthermore, 'PLUS KOSDAQ150 Active' and 'TIGER Technology Transfer Bio Active' ETFs declined by 13.46% and 7.01%, respectively, demonstrating significant variance compared to their benchmark indices.
Timefolio Asset Management is facing mounting challenges regarding its management capabilities in the KOSDAQ active ETF sector. The firm suffered setbacks due to the suspension of trading in AITC following a disclaimer of opinion from auditors, resulting in material portfolio damage. Additionally, a sharp price drop in Samchundang Pharm further weighed on performance. Timefolio's substantial exposure to AITC — holding both equity and convertible bonds — underscores a lack of risk diversification. Unlike its agile private fund days, the firm now faces constraints due to larger AUM, making rapid portfolio adjustments more difficult.
Related News
Mid- and Small-cap Growth Stocks Shaken in Volatile Market... KOSDAQ Active ETFs Struggle - Financial NewsKOSDAQ Active Exchange-Traded Funds, which were listed last month with high expectations, received mixed results due to the rollercoaster market conditions. Considering that KOSDAQ, the underlying index for both ETFs, fell by 7.99%, 'KoAct KOSDAQ Active' achieved a similar return, while 'TIME KOSDAQ Active' experienced a larger decline.
“Getting Bigger but Not as Before”... ‘Timefolio’ in a Dilemma with Stocks and Convertible Bonds - Kuki NewsTimefolio Asset Management, known as the 'absolute powerhouse' in the domestic private equity market and making a grand entrance in the KOSDAQ active ETF market, is facing successive adverse events